RxDoctor Payments Data

Elizabeth Ho, MD

Internal Medicine · Horseheads, NYNPI 1912974619

Payments from drug & device makers

$2,571in general payments, 2019–2025

Across 48 payments — averaging $53.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$487
  • GSK$304
  • Novo Nordisk$270
  • Abbott$199
  • AbbVie$197
  • Johnson & Johnson$165
  • plus $948 from 9 others

What the payments were for

  • Food & beverage$2,55399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,571 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$98,661
Medicare patients
196
Services billed
1,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol89$112,507
EliquisApixaban88$96,519
TrulicityDulaglutide31$75,478
JardianceEmpagliflozin46$61,812
OzempicSemaglutide33$54,571
RybelsusSemaglutide27$49,996
XareltoRivaroxaban24$33,374
JanuviaSitagliptin Phosphate17$26,730
Xigduo XrDapaglifloz Propaned/Metformin16$19,158
CreonLipase/Protease/Amylase14$17,876
Synjardy XrEmpagliflozin/Metformin Hcl19$16,945
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$13,379
GemtesaVibegron12$11,482
Bydureon BciseExenatide Microspheres12$9,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$487$112,50789 claims
Novo NordiskOzempic, Rybelsus$270$104,56760 claims
PfizerEliquis$142$96,51988 claims
Boehringer IngelheimJardiance, Synjardy Xr$62$78,75765 claims
Lilly USA, LLCTrulicity$121$75,47831 claims
Johnson & JohnsonXarelto$165$33,37424 claims
GSKAnoro Ellipta, Trelegy Ellipta, Arexvy$304$26,19542 claims
AbbVieCreon, Synthroid$197$19,82754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Horseheads

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →